Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹16,867 Cr
Revenue (TTM)
₹1,419 Cr
Net Profit (TTM)
₹20 Cr
ROE
-0.6 %
ROCE
2.6 %
P/E Ratio
839.1
P/B Ratio
2.9
Industry P/E
48.01
EV/EBITDA
43.3
Div. Yield
0 %
Debt to Equity
0.1
Book Value
₹507.5
EPS
₹2.4
Face value
1
Shares outstanding
114,621,201
CFO
₹--
EBITDA
₹--
Net Profit
₹--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Onesource Specialty Pharma
| -18.7 | 13.6 | -9.0 | 0.2 | -- | -- | -- |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Onesource Specialty Pharma
|
1,471.6 | 16,867.1 | 1,419.3 | 20.1 | 8.4 | 0.5 | 839.1 | 2.9 |
| 2,257.8 | 18,500.8 | 1,215.1 | 284.8 | 28.7 | 21.1 | 64.5 | 12.2 | |
| 676.3 | 13,282.8 | 7,266.8 | 627.5 | 11.9 | 12.6 | 21.1 | 2.4 | |
| 587.2 | 14,551.9 | 5,092.5 | 545.5 | 15.9 | 14.1 | 26.7 | 3.5 | |
| 856.6 | 13,645.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 31.5 | 2.1 | |
| 957.9 | 17,149.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11 | 2.0 | |
| 143.1 | 19,028.2 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 767.9 | 12,649.5 | 1,284.3 | 134.4 | -- | 30.7 | 94.1 | 10.4 | |
| 419.9 | 16,903.3 | 3,720.2 | 352.1 | 13.7 | 8.2 | 48 | 3.6 | |
| 1,215.6 | 19,800.5 | 3,151.0 | -10.0 | 8.4 | 2.5 | 900 | 4.3 |
No Review & Analysis are available.
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and... internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India. Read more
Incorporated
2007
Chairman
Arun Kumar
Managing Director
Neeraj Sharma
Headquarters
Navi Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Onesource Specialty Pharma Ltd is ₹1,471.60 (NSE) and ₹1,471.55 (BSE) as of 18-Mar-2026 IST. Onesource Specialty Pharma Ltd has given a return of 0.23% in the last 1 years.
The P/E ratio of Onesource Specialty Pharma Ltd is 839.07 times as on 18-Mar-2026, a 1648 premium to its peers’ median range of 48.01 times.
The P/B ratio of Onesource Specialty Pharma Ltd is 2.90 times as on 18-Mar-2026, a 6 discount to its peers’ median range of 3.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
3.41
|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2025
|
0.00
|
3.41
|
The 52-week high and low of Onesource Specialty Pharma Ltd are Rs 2,248.00 and Rs 1,057.00 as of 19-Mar-2026.
Onesource Specialty Pharma Ltd has a market capitalisation of ₹ 16,867 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Onesource Specialty Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-14.70
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.